Transperineal laser treatment for prostate cancer
Transperineal Laser Ablation Treatment for Prostate Cancer Registry: a Retrospective and Multicenter Evaluation
This study is looking at how safe and effective a new laser treatment for localized prostate cancer is, by gathering information from patients who have tried it.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | Male |
| Sponsor | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Academic / other |
| Locations | 1 site (Amsterdam) |
| Trial ID | NCT05163197 on ClinicalTrials.gov |
What this trial studies
This observational registry collects data on the safety and feasibility of transperineal laser ablation (TPLA) for treating localized prostate cancer. The study aims to evaluate functional and oncological outcomes while determining baseline patient characteristics in a multicenter cohort. By analyzing data from patients who have undergone TPLA, the registry seeks to provide insights into the long-term effectiveness of this minimally invasive focal therapy compared to standard radical treatments.
Who should consider this trial
Good fit: Ideal candidates for this study are males with histologically confirmed localized prostate cancer who have undergone TPLA treatment.
Not a fit: Patients under 18 years old will not benefit from this study as they do not meet the eligibility criteria.
Why it matters
Potential benefit: If successful, this approach could offer a safer and more effective treatment option for prostate cancer, potentially preserving patients' quality of life.
How similar studies have performed: While pilot studies have shown TPLA to be safe and feasible, the long-term outcomes remain largely unknown, indicating this is a novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male, histological-confirmed disease of localized prostate cancer, TPLA treatment for PCa is performed Exclusion Criteria: * Age \< 18 years
Where this trial is running
Amsterdam
- Amsterdam University Medical Centers — Amsterdam, Netherlands (Recruiting)
Study contacts
- Principal investigator: J. R. Oddens, MD, PhD — Principal Investigator
- Study coordinator: L. A. van Riel, MD
- Email: l.a.vanriel@amsterdamumc.nl
- Phone: +31 6 50 06 30 94
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.